Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

信銘生命科技集團有限公司
Aceso Life Science Group Limited
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 00474)

FURTHER DELAY IN DESPATCH OF CIRCULAR

References are made to (i) the announcement of Aceso Life Science Group Limited (the "**Company**") dated 15 July 2025 in relation to the Disposal, which constitutes a major transaction of the Company under Chapter 14 of the Listing Rules (the "**Announcement**"); and (ii) the announcement of the Company dated 7 August 2025 in relation to the grant of a Waiver (the "**Delay Announcement**"). Unless the context otherwise requires, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement and the Delay Announcement.

According to Rule 14.41(a) of the Listing Rules, the Company is required to despatch a circular to the Shareholders within 15 business days after publication of the Announcement, i.e. on or before 5 August 2025.

As stated in the Delay Announcement, the Company has applied for, and the Stock Exchange has granted, a Waiver to the Company, and the circular was expected to be despatched to the Shareholders on or before 26 August 2025.

As additional time is required for the Company to incorporate the relevant information in the circular, including but not limited to indebtedness statement and working capital statement, the Company has made a second application to the Stock Exchange for a waiver from strict compliance with Rule 14.41(a) of the Listing Rules (the "**Second Waiver Application**") for a further extension of the despatch date of the circular to a date falling on or before 31 August 2025.

Further announcement will be made by the Company when there is any update on the Second Waiver Application.

By Order of the Board
Aceso Life Science Group Limited
Zhiliang Ou
Executive Director

Hong Kong, 26 August 2025

As at the date of this announcement, the board of Directors comprises two executive Directors, namely Dr. Zhiliang Ou, J. P. (Australia) and Mr. Fok Chi Tak; one non-executive Director, namely Ms. Jiang Yang; and three independent non-executive Directors, namely Mr. Chan Ming Sun Jonathan, Mr. Lam Kwan Sing and Mr. Mak Yiu Tong.